• 5-FU is the first-line chemotherapy for colorectal cancer; its use is associated with severe long-term gastrointestinal side-effects. Mechanisms underlying 5-FU-induced gastrointestinal dysfunction have not been investigated in depth.
• These findings provide insight into the mechanisms underlying chemotherapy-induced gastrointestinal dysfunction.
Abstract
Background The use of the anticancer chemotherapeutic agent 5-fluorouracil (5-FU) is often limited by nausea, vomiting, constipation, and diarrhea; these side-effects persist long after treatment. The effects of 5-FU on enteric neurons have not been studied and may provide insight into the mechanisms underlying 5-FU-induced gastrointestinal dysfunction. Methods Balb/c mice received intraperitoneal injections of 5-FU (23 mg/kg) 3 times/week for 14 days. Gastrointestinal transit was analysed in vivo prior to and following 3, 7, and 14 days of 5-FU treatment via serial x-ray imaging. Following 14 days of 5-FU administration, colons were collected for assessment of ex vivo colonic motility, gross morphological structure, and immunohistochemical analysis of myenteric neurons. Fecal lipocalin-2 and CD45 + leukocytes in the colon were analysed as markers of intestinal inflammation. Key Results Short-term administration of 5-FU (3 days) increased gastrointestinal transit, induced acute intestinal inflammation and reduced the proportion of neuronal nitric oxide synthaseimmunoreactive neurons. Long-term treatment (7, 14 days) resulted in delayed gastrointestinal transit, inhibition of colonic migrating motor complexes, increased short and fragmented contractions, myenteric neuronal loss and a reduction in the number of ChAT-immunoreactive neurons after the inflammation was resolved. Gross morphological damage to the colon was observed following both short-and longterm 5-FU treatment. Conclusions & Inferences Our
INTRODUCTION
Colorectal cancer (CRC) is a leading cause of cancer related mortality, [1] [2] [3] leading to over 1 million deaths annually 4 ; it is one of the most frequently diagnosed cancers worldwide. Due to late stage diagnosis approximately 50% of patients have metastasis to surrounding tissues, most frequently to the liver. 5 Therefore, dual therapy consisting of chemotherapy and surgical resection is common. 6 Since the discovery of fluoropyrimidines in the 1950's, 5-fluorouracil (5-FU) has been the backbone of therapy for many solid tumors and is considered as the standard first line therapy for metastatic CRC. 7 5-fluorouracil is an analogue of uracil with a fluorine atom at the C-5 position in place of hydrogen. 8 Upon entering a cell, 5-FU is converted intracellularly to several active metabolites: fluorodeoxyuridine monophosphate, fluorodeoxyuridine triphosphate, and fluorouridine triphosphate. These active metabolites exert their cytotoxic effects via misincorporation of fluoronucleotides into RNA and inhibition of nucleotide synthetic enzyme thymidylate synthase. 9 Combination therapies including 5-FU are reported to improve response rates for advanced CRC by 40-50%, 10, 11 however, severe gastrointestinal side-effects such as nausea, vomiting, constipation, and diarrhea remain significant hurdles in the clinical application of 5-FU. It has been suggested that 5-FU-induced gastrointestinal dysfunction results from inflammation, epithelial degradation, and intestinal ulceration triggering intestinal mucositis. 12 However, recent evidence suggests that 5-FU induced gastrointestinal dysmotility outlasts intestinal mucositis. 13 One system that has been overlooked in 5-FU-induced gastrointestinal dysfunction is the enteric nervous system (ENS), embedded within the wall of the gastrointestinal tract and controlling its functions. 14 Neuronal loss and phenotypic changes within the ENS following chemotherapeutic administration of other agents, cisplatin and oxaliplatin, have been found to result in downstream effects on gastrointestinal muscle tone and transit. 15, 16 The aims of this study were to investigate the effects of short-and long-term 5-FU treatment on: (i) gastrointestinal transit time and gastric emptying; (ii) ex vivo colonic motility functions; (iii) histological architecture of the colonic mucosa; (iv) level of inflammation in the colon; and (v) the total number of myenteric neurons and subpopulations of inhibitory and excitatory neurons controlling colonic motility.
MATERIALS AND METHODS
All procedures were approved by the Victoria University Animal Experimentation Ethics Committee and performed in accordance with the guidelines of the National Health and Medical Research Council Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.
Animals
Male Balb/c mice aged 6-8 weeks (18-25 g) supplied from the Animal Resources Centre (Perth, Australia) were used for the experiments. Mice had free access to food and water and were kept under a 12 h light/dark cycle in a well-ventilated room at an approximate temperature of 22°C. Mice acclimatized for up to 7 days prior to the commencement of in vivo intraperitoneal injections. A total of 42 mice were used for this study.
In vivo 5-FU injections
Mice received intraperitoneal injections of 5-FU (23 mg/kg; SigmaAldrich, Castle Hill, NSW, Australia), 3 times a week via a 26 gauge needle. 5-FU was dissolved in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich) to make 1 M/L stock solution refrigerated at À20°C. The stock was then defrosted and diluted with sterile water to make 0.1 M/L (10% DMSO) solutions for intraperitoneal injections. The dose of 5-FU was calculated to be equivalent to standard human dose per body surface area. 17 The low doses of 5-FU (10-40 mg/kg) have been shown to have antitumor efficacy in mouse models of cancer. 18 Sham-treated mice received 10% DMSO in sterile water via intraperitoneal injection three times a week via a 26 gauge needle. The injected volumes were calculated to the body weight; the maximum volume did not exceed 200 lL per injection. Mice were euthanized via cervical dislocation at 3 (2 treatments), 7 (3 treatments), and 14 (6 treatments) days after the first injection and colon was collected for in vitro experiments.
The training/conditioning with restraint were done by placing the restrainer into the mouse cages at least 24 h prior to the x-ray procedure. Gastrointestinal transit was studied by x-ray prior to first treatment (day 0) and following 3, 7, and 14 days of 5-FU treatment. The contrast agent, 0.4 mL of suspended barium sulfate (X-OPAQUE-HD, 2.5 g/mL), was administered via oral gavage. Radiographs of the gastrointestinal tract were performed using a HiRay Plus Porta610HF x-ray apparatus (JOC Corp, Kanagawa, Japan; 50 kV, 0.3 mAs, exposure time 60 ms). Mice were immobilized in the prone position by placing them inside a transparent plastic restraint tube with partly open front side for breathing which comfortably restrains animal movement essential for maximum of 1-2 min for successful x-ray imaging. X-rays were captured using Fujifilm cassettes (24 9 30 cm) immediately after administration of barium sulfate (T0) every 5 min for the first hour, every 10 min for the second hour, then every 20 min through to 480 min (T480). Animals were closely monitored during and after all procedures. Images were developed via a Fujifilm FCR Capsula XLII and analysed using eFilm 4.0.2 software. Speed of gastrointestinal transit was calculated as time in minutes taken to reach each region of the gastrointestinal tract (stomach, small intestines, cecum, and large intestines). Organ emptying was calculated as the time taken for complete barium emptying from specific gastrointestinal regions (stomach, small intestines).
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Colonic motility experiments
The entire colon was removed from day 14 sham and 5-FU-treated mice and set up in organ-bath chambers to record motor patterns in vitro. 15 Briefly, the colon was placed into warmed (35°C), oxygenated physiological saline until the fecal pellets were expelled. The empty colon was cannulated at both ends and arranged horizontally in an organ-bath chamber. The proximal end of the colon was connected to a reservoir containing oxygenated physiological saline to maintain intraluminal pressure. The distal end was attached to an outflow tube that provided a maximum of 2 cm H 2 O back-pressure. Organ baths were continuously superfused with oxygenated physiological saline solution and preparations were left to equilibrate for 30 min. Contractile activity of each segment was recorded with a Logitech Quickcam Pro camera positioned 7-8 cm above the preparation. Videos (2 9 20 min) of each test condition were captured and saved in avi format using VirtualDub software (Avery Lee, Cambridge, MA, USA) (version 1.9.11).
Colonic migrating motor complexes (CMMCs) were defined as propagating contractions directed from the proximal to the distal end of the colon which travelled more than 50% of the colon length. [22] [23] [24] Contractions that propagated less than 50% colon length were considered to be short contractions (SCs). Incomplete non-propagating phasic contractions occurring concurrently at different parts of the colon rather than propagating over the length of the colon were defined as fragmented contractions (FCs). Recordings were used to construct spatiotemporal maps using inhouse edge detection software. 25 Spatiotemporal maps plot the diameter of the colon at all points during the recording allowing contractile motor patterns to be analysed with Matlab software (Mathworks, Natick, MA, USA) (version 12).
Drugs used
Hexamethonium Bromide (HEX; Sigma-Aldrich) and tetrodotoxin (TTX) (Abcam, Cambridge, MA, USA) were prepared as stock solutions and diluted in physiological saline daily before addition to preparations.
Histology
The colon was harvested and placed in a 10% formalin solution overnight and then transferred into 70% ethanol the following day. Paraffin embedded colon sections were cut 5 lm thick and de-waxed in a 60°C oven for 30 min. To examine the morphological changes to the colon, a standard Hematoxylin and Eosin staining protocol was followed. 26, 27 Immunohistochemistry in wholemount preparations
Colon sections (2-3 cm) were placed in oxygenated phosphatebuffered saline (PBS; pH 7.2) containing nicardipine (3 lM; SigmaAldrich) for 20 min to inhibit smooth muscle contractions.
Samples were cut open along the mesenteric border, cleared of their contents, maximally stretched and dissected mucosa up to expose the myenteric plexus attached to the longitudinal muscle layer. Tissues were fixed with Zamboni's fixative (2% formaldehyde, 0.2% picric acid) overnight at 4°C. Preparations were cleared of fixative by washing 3 9 10 min with DMSO followed by 3 9 10 min washes with PBS. Fixed tissues were stored at 4°C in PBS for a maximum of 5 days.
Wholemount preparations were incubated with 10% normal donkey serum (Chemicon, EMD Millipore Corporation, Billerica, MA, USA) for 1 h at room temperature. Tissues were then washed (2 9 5 min) with PBS and incubated with primary antibodies against Protein Gene Product 9.5 (PGP9.5) (chicken, 1 : 500; Abcam), neuronal nitric oxide synthase (nNOS; goat, 1 : 500; Abcam), and choline acetyl transferase (ChAT; goat, 1 : 200; Abcam) overnight at 4°C. Tissues were then washed in PBS (3 9 10 min) before incubation with species-specific secondary antibodies labeled with different fluorophores: donkey antichicken Alexa 594 (1 : 200; Jackson Immuno Research Laboratories, West Grove, PA, USA) and donkey anti-goat Alexa 488 (1 : 200; Jackson Immuno Research Laboratories) for 2 h at room temperature. Wholemount preparations were given 3 9 10 min final washes in PBS and then mounted on glass slides using fluorescent mounting medium (DAKO, Glostrup Municipality, Hovedstaden, Denmark). Wholemount preparations were observed under a Nikon Eclipse Ti laser scanning microscope (Nikon, Tokyo, Japan), eight randomly chosen images from each preparation were captured with a 209 objective and processed using NIS Elements software (Nikon). The number of PGP9.5, nNOS, and ChAT immunoreactive neurons was quantified in the myenteric ganglia within a 2 mm 2 area of each preparation.
Immunohistochemistry in cross-sections
Colon sections (1-2 cm) were placed in oxygenated PBS containing nicardipine (3 lM; Sigma-Aldrich) for 20 min to inhibit smooth muscle contractions. Samples were cut open along the mesenteric border, cleared of their contents, and pinned mucosa up without stretching. Tissues were fixed with Zamboni's fixative overnight at 4°C. Preparations were cleared of fixative by washing 3 9 10 min with DMSO (Sigma-Aldrich) followed by 3 9 10 min washes with PBS. After washing, tissues were embedded in 100% OCT and frozen using liquid nitrogen (LN 2 ) and isopentane (2-methyl butane) and stored in À80°C freezer. Tissues were cut at 20 lm section thickness using Leica CM1950 cryostat (Leica Biosystems, Wetzlar, Hesse, Germany), adhered to slides and allowed to rest for 30 min at room temperature before processing.
Cross-section preparations were incubated with 10% normal donkey serum (Chemicon) for 1 h at room temperature. Tissues were then washed (2 9 5 min) with PBS and incubated with primary antibodies against CD45 (Rat, 1 : 500; BioLegend, San Diego, CA, USA), overnight at 4°C. Sections were then washed in PBS (3 9 10 min) before incubation with secondary antibodies labeled with fluorophore donkey anti-rat Alexa 488 (1 : 200; Jackson Immuno Research Laboratories) for 2 h at room temperature. The sections were given 3 9 10 min final washes in PBS and then cover slipped using fluorescence mounting medium (DAKO). Sections were viewed under a Nikon Eclipse Ti laser scanning microscope (Nikon), eight randomly chosen images from each preparation were captured with a 209 objective and processed using NIS Elements software (Nikon). The number of CD45 + immunoreactive cells was quantified within a 2 mm 2 area in every colonic section.
Imaging
Three dimensional (z-series) images of wholemount preparations were taken using a Nikon Eclipse Ti laser scanning microscope (Nikon). Fluorophores were visualized using excitation filters for Alexa 594 Red (excitation wavelength 559 nm), Alexa 488 (excitation wavelength 473 nm), and Alexa 405 (excitation wavelength 405 nm). Z-series images were taken at step size of 1.75 lm (1600 9 1200 pixels).
Quantification of fecal lipocalin-2
Fresh fecal pellets were collected from mice after 3, 7, and 14 days of 5-FU administration and stored immediately at À80°C. Fecal samples were thawed and suspended in PBS with 0.1% Tween (100 mg/mL) overnight prior to processing. The next day samples were centrifuged at 13.8 g at 4°C for 10 min. Samples were then agitated and centrifuged for another 5 min at 12 000 rpm at 4°C. Supernatant was collected and lipocalin-2 levels were quantified using DuoSET ELISA Mouse Lipocalin-2 kit (R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Data were assessed using two-way ANOVA, Welch's two-tailed t-test, and Student's two-tailed t-test. Analyses were performed using Graph Pad Prism (Graph Pad Software Inc., San Diego, CA, USA). Data are presented as mean AE SEM. Value differences were considered statistically significant at p < 0.05.
RESULTS
Altered gastrointestinal transit following 5-FU administration
To determine the effects of 5-FU administration on gastrointestinal transit, series of radiographic images were used to track barium sulfate throughout the gastrointestinal tract before the first injection (day 0), after two injections (day 3), three injections (day 7), and six injections (day 14; Figs 1 and 2, Table 1 ). The speed of barium movement was calculated by tracing barium entry from one part of the gastrointestinal tract to the next. After 3 days of 5-FU administration, movement of barium in both the cecum and colon was faster than before treatment ( Fig. 2A) , however, after 7 and 14 days of 5-FU administration barium movement was significantly delayed compared to day 0 in the cecum and colon ( Fig. 2A , Table 1 ). Although tracing barium movement allowed analysis of real time transit speed, gastrointestinal organ filling and emptying does not happen simultaneously, thus we further analysed the time taken for complete barium emptying from specific regions.
No changes in gastric emptying time were observed at day 3 of 5-FU administration, but significant delays in gastric emptying were seen after 7 and 14 days of 5-FU administration (Fig. 2B, Table 1 ). Intestinal emptying was faster after 3 days of 5-FU administration, but significantly delayed after both 7 and 14 days of 5-FU administration (Fig. 2C, Table 1 ).
Pellet formation time was decreased after 3 days of 5-FU administration (Fig. 2D ), but significantly increased after 7 and 14 days of 5-FU administration (Fig. 2D) . Thus, increased intestinal transit was observed after short-term 5-FU treatment, while prolonged treatment induced delays in gastrointestinal transit.
Changes in colonic motility following 5-FU treatment
To investigate effects of 5-FU treatment on colonic motility, excised colons were studied in organ bath experiments at day 14 of 5-FU treatment. The total number of contractions (including all types of motor patterns in the colon: CMMCs, short and FCs, Fig. 3A ) was increased in colons from 5-FU-treated animals compared to sham-treated mice (sham: 27.7 AE 1.4, 5-FU: 36.1 AE 2.1, p < 0.01, Fig. 3B ). To determine if this increase was due to changes in a specific type of motor activity, the frequency, proportion, and propagation speed were analysed for each type of motor pattern.
Colonic migrating motor complexes were defined as sustained anally directed contractions propagating more than 50% of the colon length. Colonic migrating motor complexes are mediated mainly by myenteric neurons, although inputs from the mucosa may modulate their activity. 28 In vivo treatment with 5-FU was associated with a decrease in the frequency of CMMCs in comparison with sham-treated mice (sham: 11.2 AE 0.6, 5-FU: 3.5 AE 1.0, p < 0.0001, Fig. 3B ). Similarly, the proportion of CMMCs following 5-FU treatment was significantly decreased compared to sham-treated mice (sham: 41.1 AE 3.0%, 5-FU: 12.4 AE 3.8%, p < 0.0001, Fig. 3C ). No significant difference in the speed of CMMCs was found between sham-treated and 5-FU-treated mice (sham: 2.9 AE 0.2 mm/s, 5-FU: 2.3 AE 0.3 mm/s, Fig. 3D ).
Contractions that propagated less than 50% of the colon length were termed SCs (Fig. 3A) . To investigate whether neurogenic components are involved in the recorded colonic motor patterns, a voltage-gated sodium channel blocker TTX and a nicotinic cholinergic antagonist HEX were added into the organ baths. TTX (1 lM, 20 min) abolished CMMCs, SCs, and FCs in colons from both sham and 5-FU-treated mice (Fig. 3E) , indicating that these motility patterns are neurogenic. However, a persistent TTX-resistant tonic constriction in the distal part of the colon blocked by HEX (100 lM, 20 min) was observed in sham-treated mice. In 5-FU-treated mice, TTX-resistant tonic constrictions were prominent in both proximal and distal parts of the colon; the proximal tonic constriction was not blocked by application of HEX (Fig. 3E) .
Morphological damage to the colon following 5-FU administration
Colonic architecture from sham-treated animals at days 3, 7, and 14 appeared healthy with a visible brush border and uniform crypts (Fig. 4A-C) . Histological examination of the colon at day 3 from the 5-FUtreated group demonstrated no obvious changes to the epithelial brush border; however, there was a severe loss of colonic crypts and goblet cells and cellular infiltration within the lamina propria when compared to the sham-treated group (Fig. 4A and A' ). By days 7 and 14, there was thickening of the epithelial brush border indicative of regeneration of the colonic crypts in the 5-FU-treated groups, but they still appeared short, distended, and disorganized with an increased number of goblet cells (Fig. 4B' and C' ) when compared to colon from the sham-treated group (Fig. 4B and C) .
Intestinal inflammation following 5-FU treatment
To investigate if 5-FU treatment causes inflammation, immune cell infiltration in the colon and the concentration of a neutrophil gelatinase-associated protein, lipocalin-2, a highly sensitive biomarker for intestinal inflammation 29, 30 in fecal samples were analysed.
Immune cells in colonic-cross sections were labeled with a pan leukocyte marker anti-CD45 antibody following 3 (Fig. 5A and A'), 7 ( Fig. 5B and B' ), and 14 ( To determine if 5-FU administration was associated with changes in subpopulations of myenteric neurons controlling intestinal muscle activity, inhibitory muscle motor, and interneurons IR for nNOS (Fig. 7) and neurons IR for ChAT (Fig. 8) were analysed.
Fewer nNOS-IR neurons were observed at days 3 (sham: 357 AE 7; 5-FU: 286 AE 3, p < 0.0001) and 14 (sham: 380 AE 11; 5-FU: 310 AE 3, p < 0.0001) following 5-FU administration (Fig. 7A' and C ) when compared to sham (Fig. 7A and C) . However, no reduction in the number of nNOS-IR neurons from the 5-FU-treated group was observed at day 7 (sham: 363 AE 5; 5-FU: 341 AE 4; Fig. 7B, B' and D) . The proportion of nNOS-IR neurons was reduced on day 3 (sham: 29.5 AE 0.3%; 5-FU: 23.8 AE 0.3%) when compared to sham (p < 0.01, Fig. 7E ), but not on days 7 (sham: 29.3 AE 0.6; 5-FU: 29.7 AE 0.3) and 14 (sham: 30.9 AE 0.9; 5-FU: 28.5 AE 0.4, Fig. 7E ).
The total number of ChAT-IR neurons increased on day 3 (sham: 294 AE 4; 5-FU: 319 AE 4), but decreased on days 7 (sham: 322 AE 2; 5-FU: 300 AE 4) and 14 (sham: 320 AE 3; 5-FU: 282 AE 5) following 5-FU administration (Fig. 8A', B' , C', and D) when compared to the shamtreated group (Fig. 8A-D) . However, no significant difference in the proportion of ChAT-IR neurons was observed at any time point after 5-FU administration began (Fig. 8E) .
DISCUSSION
This study is the first to examine 5-FU-induced enteric neuropathy and its effect on gastrointestinal function. Our results show that 5-FU administration causes a significant increase in gastrointestinal transit time at day 3, but delays in intestinal and gastric emptying at days 7 and 14. Significant reductions in the frequency and proportion of CMMCs, but increased frequency and proportions of short and FCs were prominent after 14 days of 5-FU treatment. All types of contractions were abolished by TTX; a residual tonic constriction in the distal colon was blocked by HEX in both sham and 5-FU-treated mice. A TTX-resistant tonic constriction of the proximal colon seen in 5-FU-treated mice was not blocked by HEX. Severe crypt ablation and mucosal destruction occurred in the colon at day 3. Consistent crypt disorganization and hypoplasia persisted throughout the experimental period; however, mucosal barrier regeneration was evident after both 7 and 14 days. Acute inflammation, confirmed by increased levels of fecal lipocalin-2 and CD45 positive leukocytes in the colon, was seen on day 3 of 5-FU treatment but subsided by days 7 and 14. Loss of myenteric neurons was seen on days 7 and 14, accompanied by 90 AE 3 66 AE 3**** 105 AE 4*** 113 AE 4**** *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, significantly different to Day 0 (n = 5 per/group).
reduced numbers of ChAT-IR neurons at these time points.
Although 5-F U is routinely used in the treatment of CRC and is known to cause gastrointestinal side-effects, the neurological mechanisms underlying these sideeffects have not been studied. 31, 32 Our study demonstrates that, while short-term 5-FU treatment accelerates overall gastrointestinal transit without a change in gastric emptying, more prolonged treatment results in significant delays to overall gastrointestinal transit, gastric emptying and intestinal emptying. Our findings are consistent with previous studies showing that shortand long-term administration of the chemotherapeutic agent cisplatin differentially alters gastrointestinal transit. 19, 20 Our findings suggest that mechanisms underlying these differential changes in transit are different. Accelerated gastrointestinal transit observed after 3 days of treatment was associated with acute intestinal inflammation and reduced proportions of nNOS-IR neurons. Intestinal inflammation was resolved after days 7 and 14 when delays to overall gastrointestinal transit, gastric, and intestinal emptying, and colonic dysmotility were observed. The loss of myenteric neurons observed at these time points might contribute to the functional changes in the gastrointestinal tract. Gastric and intestinal transit has previously been investigated using radioactivity retention technique in rats where it was found that delayed gastric empting and increased fundus and duodenum muscle contractions occurred 3 and 15 days after a single high dose of 5-FU (150 mg/kg) injection. 13 However, our study is the first to use radiographic analysis to evaluate overall gastrointestinal transit alongside ENS damage following 5-FU administration in mice. Postinflammatory delays to gastric and intestinal emptying have been reported in a plethora of gastrointestinal disorders. [33] [34] [35] Gastric emptying of solids is significantly delayed in patients with postinfectious functional dyspepsia, irritable bowel syndrome, non-obstructive Crohn's disease and colitis. Mucosal inflammation, epithelial degradation and intestinal ulceration, manifesting as mucositis, following 5-FU administration have been suggested as causes of gastrointestinal dysfunction. 12 Our results show that, while short-term 5-FU treatment was associated with destruction of the epithelial brush border and severe loss of colonic crypts and goblet cells, chronic treatment did not worsen epithelial damage. In fact regeneration of mucosa was evident during chronic 5-FU treatment, although crypts still appeared shorter, distended, and disorganized. These results are consistent with previous findings in the rat duodenum following 3 days of 5-FU treatment, where loss of crypt architecture, shortening of villi and inflammatory infiltration in the lamina propria was reported. 13 This was followed by the restoration of intestinal villi and crypts following 15 days of 5-FU treatment, but with sparse neutrophil infiltration in the muscular layer. 13 Such evidence indicates that duodenal mucosal inflammation resolves during 15 days of 5-FU treatment.
Both in vitro and in vivo treatment with 5-FU promote the attraction of inflammatory cells. 39 Intestinal inflammation is associated with gastrointestinal dysmotility both at the site of inflammation and at distant non-inflamed sites. [40] [41] [42] Further to this a number of inflammatory mediators have been implicated in both short-and long-term smooth muscle contractility changes. 43 Accordingly, many gastrointestinal side-effects experienced during and after 5-FU administration have been attributed to inflammationinduced mucosal damage which we observed in the rat model of acute toxicity induced by a high dose (150 or 300 mg/kg) of 5-FU (R. Abalo, unpublished data) and in this study after a short-term treatment of mice with a low dose (23 mg/kg) of 5-FU. However, 5-FU-induced gastrointestinal dysmotility appears to outlast intestinal mucositis, 13 indicating that a more complex and multifaceted pathophysiology is at play. Our results show that chronic 5-FU administration results in significant neuronal loss in the myenteric plexus of the colon at days 7 and 14 when intestinal inflammation subsided. Our findings are consistent with previous studies investigating effects of platinum-based anticancer chemotherapeutics, which also demonstrated that long-term treatments induce loss of myenteric neurons. 15, 16 However, 5-FU treatment induced less severe damage to myenteric neurons with 12% loss at day 14 compared to 25% of myenteric neuronal loss at day 14 of oxaliplatin treatment. 15 Although previous studies demonstrated that the loss of enteric neurons does not necessarily lead to changes in CMMCs 44, 45 our results demonstrated that the loss of myenteric neurons correlated with colonic dysmotility in 5-FU-treated mice. The loss of myenteric neurons leads to long-term alterations in gastrointestinal functions as was shown in rats after cisplatin treatment 16 and mice after oxaliplatin treatment. 15 5-FU treatment inhibited CMMCs, but the total number of contractions of the isolated colon was significantly increased due to an increase in the number and proportion of short and FCs. Short and FCs play a vital role in the construction of productive motor patterns in the healthy intestine. 25 Short distance contractions result in a segmenting motor pattern essential for mixing and absorption of colonic contents. 46 Alteration in short segmenting contractions induces intestinal dysmotility. 47 Our results demonstrated that all types of contractions were neurogenic; residual tonic constriction in the distal colon was blocked by HEX in both sham and 5-FU-treated mice. Tetrodotoxin-resistant tonic constriction in the proximal colon observed in 5-FUtreated mice was not blocked by HEX. These results suggest that there is TTX-insensitive tonic excitatory drive to the smooth muscle that presumably involves at least one nicotinic synapse and hence must involve neurons with TTX-resistant action potentials like those described by Foong et al. in the mouse submucosal plexus. 48 This activity seems to be differentially sensitive to 5-FU. Thus, initial acute inflammation caused by 5-FU treatment may have led to persistent changes in the ENS and gut dysfunction. Similarly, in animal models of intestinal inflammation, long-term gut dysfunction persists long after resolution of acute inflammation due to neuronal loss, axonal damage, and neuronal dysfunction in the myenteric plexus leading to changes in synaptic transmission between neurons and to the smooth muscles. 26, [49] [50] [51] [52] [53] [54] We found that long-term treatment with 5-FU induced loss of both excitatory (ChAT-IR) and inhibitory (nNOS-IR) neurons in the myenteric plexus. However, only nNOS-IR neuron proportions were reduced at day 3 post 5-FU treatment, which is consistent with increased intestinal transit at this time point. Loss of nNOS-IR neurons was also observed in cisplatin and oxaliplatin-treated animals 15, 16 however, ChAT-IR neurons were not investigated in these studies. Thus, our results suggest that the loss of neurons after 5-FU treatment is not restricted to a specific neurochemically defined subpopulation. Differential effects of various chemotherapeutic compounds on enteric neurons might be attributed to the differences in their mechanisms of action with platinum-based compounds having direct neurotoxicity due to platinum adducts to DNA 55 compared to inflammation-induced neuropathy associated with 5-FU treatment. 13 Damage to the intestinal smooth muscles, alterations in neuromuscular transmission, smooth muscle sensitivity to neurotransmitters and morphological and functional changes of interstitial cells of Cajal might be also involved in 5-FU-induced dysmotility and these require further investigation.
In conclusion, this study is the first to demonstrate that 5-FU administration induces accelerated gastrointestinal transit associated with acute intestinal inflammation at day 3 post-treatment, which may have led to persistent changes in the ENS and gastrointestinal dysfunctions: delayed gastrointestinal transit, gastric and intestinal emptying, and colonic dysmotility. The loss of myenteric neurons observed at days 7 and 14 of treatment may contribute to the functional changes in the gastrointestinal tract. Further research investigating the effects of 5-FU on the electrophysiological properties of myenteric neurons is warranted.
